Oxeia named a One Nucleus finalist for annual BioNewsRound Award for the company’s announcement of the initiation of Phase 2 trial for its drug treatment for concussion, OXE103. The award, which recognizes life science companies with exciting developments, will be announced at the annual Genesis conference on December 10, 2020.